Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal
Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...
Drug Store News10h
FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars
After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml solution, as well as a 120 mg/1.7 ml solution in a single-dose vial.
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together ...
Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003
Thursday announced the acquisition of Xbrane Biopharma AB’s R&D operations and a biosimilar candidate, establishing a footprint in the Swedish life science sector.
Icelandic Biotech Company Alvotech to Explore Listing in Stockholm
Icelandic biotechnology company Alvotech intends to explore the possibility of a Stockholm listing as it announced the acquisition of a Swedish research and development operation and drug candidate.
Dr. Reddy’s, Alvotech announce FDA acceptance of BLA for AVT03
Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. Food and Drug Administration, FDA, has accepted a 351(k) Biologic ...
Dr. Reddy’s, Alvotech announce FDA acceptance of AVT03 BLA
Dr. Reddy’s (RDY) and Alvotech (ALVO) announced that the FDA has accepted a 351(k) biologic license application submission for AVT03, developed ...
Morningstar3d
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
In May 2024, Dr. Reddy’s and Alvotech entered into a License and Supply Agreement for AVT03. Under the agreement, Alvotech is responsible for the development and manufacturing of AVT03 ...
Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03
Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03. Read more here.
Morningstar3d
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Dr. Reddy’s Laboratories Ltd. (BSE: 500124 ...
manilatimes4d
Alvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together ...